West Pharmaceutical Services, Inc.
WSTNYSEHealthcare● Active
$321.16
+$6.66(+2.12%)
Market Cap$22.7B
P/E Ratio—
52W High$330.88
52W Low$206.8
West Pharmaceutical Services, Inc. (WST) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
WST · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 23, 2026EPS Actual
$2.13
Est. $1.68 · +26.8%
Revenue
$0.84B
Est. $0.78B · +8.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 23, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 7-Quarter EPS Beat Streak
WST reports quarterly as a NYSE-listed Medical - Instruments & Supplies company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 23, 2026 | $2.08 | — | — | — | $0.84B | — |
| ▲ Q2 FY2026 | Apr 23, 2026 | $1.68 | $2.13 | +26.8% | $0.84B | $0.78B | +8.3% |
| ▲ Q1 FY2026 | Feb 12, 2026 | $1.83 | $2.04 | +11.5% | $0.81B | $0.79B | +1.3% |
| ▲ Q4 FY2025 | Oct 23, 2025 | $1.68 | $1.96 | +16.7% | $0.80B | $0.79B | +2.4% |
| ▲ Q3 FY2025 | Jul 24, 2025 | $1.51 | $1.84 | +21.9% | $0.77B | $0.73B | +5.5% |
| ▲ Q2 FY2025 | Apr 24, 2025 | $1.22 | $1.45 | +18.9% | $0.70B | $0.71B | -2.1% |
| ▲ Q1 FY2025 | Feb 13, 2025 | $1.71 | $1.82 | +6.4% | $0.75B | $0.74B | +1.1% |
| ▲ Q4 FY2024 | Oct 24, 2024 | $1.50 | $1.85 | +23.3% | $0.75B | $0.71B | +5.3% |
Q3 FY2026
Jul 23, 2026
EPS Actual
—
EPS Est.
$2.08
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 23, 2026Beat
EPS Actual
$2.13
EPS Est.
$1.68
EPS Surpr.
+26.8%
Revenue
$0.84B
Q1 FY2026
Feb 12, 2026Beat
EPS Actual
$2.04
EPS Est.
$1.83
EPS Surpr.
+11.5%
Revenue
$0.81B
Q4 FY2025
Oct 23, 2025Beat
EPS Actual
$1.96
EPS Est.
$1.68
EPS Surpr.
+16.7%
Revenue
$0.80B
Q3 FY2025
Jul 24, 2025Beat
EPS Actual
$1.84
EPS Est.
$1.51
EPS Surpr.
+21.9%
Revenue
$0.77B
Q2 FY2025
Apr 24, 2025Beat
EPS Actual
$1.45
EPS Est.
$1.22
EPS Surpr.
+18.9%
Revenue
$0.70B
Q1 FY2025
Feb 13, 2025Beat
EPS Actual
$1.82
EPS Est.
$1.71
EPS Surpr.
+6.4%
Revenue
$0.75B
Q4 FY2024
Oct 24, 2024Beat
EPS Actual
$1.85
EPS Est.
$1.50
EPS Surpr.
+23.3%
Revenue
$0.75B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $2.84 | $2.89 | $2.93 | 7 |
| Q3 FY2028 | $2.61 | $2.66 | $2.70 | 4 |
| Q2 FY2028 | $2.59 | $2.63 | $2.67 | 6 |
| Q1 FY2028 | $2.45 | $2.49 | $2.53 | 4 |
| Q4 FY2027 | $2.52 | $2.56 | $2.60 | 6 |
| Q3 FY2027 | $2.38 | $2.42 | $2.46 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.9B | $0.9B | $1.0B | 6 |
| Q3 FY2028 | $0.9B | $0.9B | $0.9B | 3 |
| Q2 FY2028 | $0.9B | $0.9B | $0.9B | 5 |
| Q1 FY2028 | $0.9B | $0.9B | $0.9B | 3 |
| Q4 FY2027 | $0.9B | $0.9B | $0.9B | 7 |
| Q3 FY2027 | $0.9B | $0.9B | $0.9B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 23, 2026 | +26.8% | $274.41 | $309.70 | +12.86% |
| ▲ Q1 FY2026 | Feb 12, 2026 | +11.5% | $246.16 | $243.61 | -1.04% |
| ▲ Q4 FY2025 | Oct 23, 2025 | +16.7% | $277.00 | $307.25 | +10.92% |
| ▲ Q3 FY2025 | Jul 24, 2025 | +21.9% | $227.31 | $279.10 | +22.78% |
| ▲ Q2 FY2025 | Apr 24, 2025 | +18.9% | $218.18 | $210.59 | -3.48% |
| ▲ Q1 FY2025 | Feb 13, 2025 | +6.4% | $322.28 | $199.11 | -38.22% |
| ▲ Q4 FY2024 | Oct 24, 2024 | +23.3% | $286.44 | $330.65 | +15.43% |
| ▼ Q3 FY2024 | Jul 25, 2024 | -12.6% | $323.77 | $277.16 | -14.40% |
Q2 FY2026+12.86%
Report Date
Apr 23, 2026
EPS Beat/Miss
+26.8%
Price Before
$274.41
Price After
$309.70
Q1 FY2026-1.04%
Report Date
Feb 12, 2026
EPS Beat/Miss
+11.5%
Price Before
$246.16
Price After
$243.61
Q4 FY2025+10.92%
Report Date
Oct 23, 2025
EPS Beat/Miss
+16.7%
Price Before
$277.00
Price After
$307.25
Q3 FY2025+22.78%
Report Date
Jul 24, 2025
EPS Beat/Miss
+21.9%
Price Before
$227.31
Price After
$279.10
Q2 FY2025-3.48%
Report Date
Apr 24, 2025
EPS Beat/Miss
+18.9%
Price Before
$218.18
Price After
$210.59
Q1 FY2025-38.22%
Report Date
Feb 13, 2025
EPS Beat/Miss
+6.4%
Price Before
$322.28
Price After
$199.11
Q4 FY2024+15.43%
Report Date
Oct 24, 2024
EPS Beat/Miss
+23.3%
Price Before
$286.44
Price After
$330.65
Q3 FY2024-14.40%
Report Date
Jul 25, 2024
EPS Beat/Miss
-12.6%
Price Before
$323.77
Price After
$277.16
Avg Beat Reaction+2.75%
Avg Miss Reaction-14.40%
Beat Rate7 / 8 quarters
Largest Move-38.22% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: WST ends December
West Pharmaceutical Services, Inc. (WST) most recently reported earnings on April 23, 2026 for Q2 FY2026, posting EPS of $2.13 — beating the analyst consensus of $1.68 by +26.8%. WST has beaten EPS estimates for 7 consecutive quarters. The next WST earnings date is expected around September 1, 2026.
Each quarter, investors track WST earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. WST revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
WST's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
WST earnings · 5 questionsWest Pharmaceutical Services, Inc.'s next earnings report is expected around September 1, 2026. WST typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; WST historically reports after market close (AMC).
WST earnings datewhen is WST earningsWST next earnings datewhen does WST report earningsWST earnings calendar
▸ Source: FMP · West Pharmaceutical Services, Inc. SEC filings · US GAAP · West Pharmaceutical Services, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026